17450-34-9Relevant articles and documents
Cell Permeable Imidazole-Desferrioxamine Conjugates: Synthesis and in Vitro Evaluation
Pramanik, Shreya,Chakraborty, Saikat,Sivan, Malavika,Patro, Birija S.,Chatterjee, Sucheta,Goswami, Dibakar
, p. 841 - 852 (2019)
Desferrioxamine (DFO), a clinically approved iron chelator used for iron overload, is unable to chelate labile plasma iron (LPI) because of its limited cell permeability. Herein, alkyl chain modified imidazolium cations with varied hydrophobicities have been conjugated with DFO. The iron binding abilities and the antioxidant properties of the conjugates were found to be similar to DFO. The degree of cellular internalization was much higher in the octyl-imidazolium-DFO conjugate (IV) compared with DFO, and IV was able to chelate LPI in vitro. This opens up a new avenue in using N-alkyl imidazolium salts as a delivery vector for hydrophilic cell-impermeable drugs.
1,3-Bis(2′-hydroxyethyl)imidazolium ionic liquids: Correlating structure and properties with anion hydrogen bonding ability
Deng, Feng,Reeder, Zachary K.,Miller, Kevin M.
, p. 2 - 9 (2014)
A series of 1,3-bis(2′-hydroxyethyl)imidazolium ionic liquids is reported where 1H NMR chemical shift values and thermal stabilities (Td), as determined by thermogravimetric analysis, are correlated with the hydrogen bonding capability of various anions ([Cl-], [Br-], [CF3CO2-], [NO 2-], [MsO-], [NO3-], [TfO-], [BF4-], [NTf2-], and [PF6-]). Use of anions with the strongest hydrogen bonding capability, such as chloride [Cl-], bromide [Br-], and trifluoroacetate [CF3CO2-], led to the furthest observed downfield chemical shift values in DMSO-d6 and the poorest thermal stabilities ([CF3CO2-] -], tetrafluoroborate [BF4-], or bis(trifluoromethylsulfonyl)imide [NTf2-] anion. Optimized structures of selected ionic liquids, as determined by density functional theory calculations at the B3LYP/6-31G + (d,p) level, indicated that the anion preferred to be located above the imidazolium ring and in close proximity to the hydroxyl groups. Calculated dissociation energies (ΔE) and a comparison of key bonding distances (C2 - H, (C2)H···X, O - H, and (O)H···X) also confirmed this structural preference. Copyright
One-pot preparation method for imidazol-1-yl-acetic acid
-
Paragraph 0030-0038, (2020/07/15)
The invention discloses a one-pot preparation method for imidazol-1-yl-acetic acid. The preparation method comprises the following specific steps: 1) dissolving imidazole in a solvent, and then carrying out an N-alkylation reaction on the formed solution and an N-alkylation reagent to obtain methyl imidazol-1-yl-acetate or ethyl imidazol-1-yl-acetate in a reaction intermediate state; and 2) addinghydrous ethanol into a reaction solution obtained in the step 1), continuing heating for a hydrolysis reaction, carrying out cooling for crystallization after the reaction is finished, and carrying out filtering and drying to obtain imidazol-1-yl-acetic acid. According to the method, the starting raw material imidazole is used as an alkali, so the use of a phase transfer catalyst is avoided; theimidazol-1-yl-acetic acid is prepared by the one-pot method, so steps are few, operation is simple, raw material variety is few, post-treatment is simple, reaction yield is high, product purity is high, reaction conditions are mild, cost is low, and safety is good; and the method accords with the trend of green chemical industry and is suitable for industrial production.
Dihydro quinazolinone derivative, as well as preparation method and application thereof
-
Paragraph 0117; 0124; 0125, (2018/07/30)
The invention relates to the technical field of medicines, in particular to a new dihydro quinazolinone derivative with the following chemical structure general formula and pharmaceutically acceptablesalts thereof, (the formula is shown in the description.), A pharmacological experiment shows that the derivative or the salt provided by the invention has higher inhibitory activity on KRAS-PDE delta protein interaction, and has higher anti-tumor activity in vitro. The invention also provides a preparation method of the derivative and the pharmaceutically acceptable salts thereof, and application to preparatioin of a KRAS-PDE delta inhibitor and an anti-tumor drug.
